Metsera (NASDAQ:MTSR) Rating Lowered to Sell at Wall Street Zen

Metsera (NASDAQ:MTSR) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

Several other equities analysts have also issued reports on MTSR. Leerink Partners began coverage on shares of Metsera in a report on Tuesday, September 9th. They issued an “outperform” rating and a $77.00 price target on the stock. Bank of America boosted their target price on Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Metsera in a research note on Wednesday, September 3rd. Guggenheim boosted their price target on Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, June 10th. Finally, Wells Fargo & Company started coverage on shares of Metsera in a research report on Friday, June 20th. They set an “overweight” rating and a $65.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $58.50.

Metsera Stock Down 0.9%

Shares of Metsera stock opened at $52.50 on Tuesday. The firm’s 50 day moving average price is $36.09 and its 200-day moving average price is $29.68. Metsera has a 52-week low of $12.30 and a 52-week high of $54.47.

Metsera (NASDAQ:MTSR) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Metsera

A number of large investors have recently bought and sold shares of MTSR. Osaic Holdings Inc. boosted its stake in shares of Metsera by 45.5% in the second quarter. Osaic Holdings Inc. now owns 946 shares of the company’s stock worth $27,000 after buying an additional 296 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Metsera by 100.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock worth $46,000 after purchasing an additional 800 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its position in Metsera by 32.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 4,293 shares of the company’s stock worth $122,000 after purchasing an additional 1,056 shares in the last quarter. Prudential Financial Inc. boosted its position in Metsera by 7.9% in the 2nd quarter. Prudential Financial Inc. now owns 16,070 shares of the company’s stock worth $457,000 after purchasing an additional 1,170 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its position in Metsera by 25.0% in the 2nd quarter. New York State Common Retirement Fund now owns 6,000 shares of the company’s stock worth $171,000 after purchasing an additional 1,200 shares in the last quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.